# CIC

Source: https://onco.cc/targets/cic/  
OnCo record `cic` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.

## Summary

Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development.

CIViC holds 11 clinical evidence items and 0 assertions across 3 variants, naming Trametinib, Vemurafenib and Selumetinib. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.76, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Hepatocellular Carcinoma, Low-Grade Glioma, NOS, Lung Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: capicua transcriptional repressor; Protein capicua homolog; KIAA0306
- Tags: cancer-genes-wave
- Symbol: CIC
- Class: transcription
- Biology: Transcriptional repressor which plays a role in development of the central nervous system (CNS). In concert with ATXN1 and ATXN1L, involved in brain development. Location: Nucleus (UniProt). Locus 19q13.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Lung cancer: CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 11 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.

## Sources

- HGNC HGNC:14214: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14214
- UniProt Q96RK0: https://www.uniprot.org/uniprotkb/Q96RK0/entry
- NCBI Gene 23152: https://www.ncbi.nlm.nih.gov/gene/23152
- Ensembl ENSG00000079432: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079432

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- trials: [Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC](https://onco.cc/trials/nct05491525/)

---
JSON: https://onco.cc/api/v1/entities/cic.json